Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. PFSCF


Primary Symbol: LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Bullboard Posts
Comment by saltajaon May 15, 2016 7:34pm
262 Views
Post# 24875379

RE:RE:Important Notice!!!!!!....Only post in BB if you think it's

RE:RE:Important Notice!!!!!!....Only post in BB if you think it'sGrapeguy, regarding PBI-4050 being used in conjunction with other drugs. Think about it from the point of view of the patient. Why would they (and their doctors advising them) agreed to go off a drug that is doing something for them to try a drug that might work based on some rat studies. We can bet on 4050 with our investment money, but for them the bet is their health.

4050 has passsed a 1b showing it is safe in patients, so there is little risk of side effects from the two drugs. To me it just makes sense to design a trial this way. The T2+MS trail was the same way. I suspect this approach to be the norm in trails.

IMHO
Bullboard Posts